Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients

Sandrine Hayette, Mauricette Michallet, Marie Laurence Baille, Jean Pierre Magaud, Franck E. Nicolini

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

21 Citations (Scopus)

Résumé

Quantitative monitoring of imatinib mesylate (IM)-resistant, mutated BCR-ABL+ cells during the follow-up of CML could be useful for optimizing therapeutic management. We retrospectively analyzed T315I mutated BCR-ABL clones throughout the CML history of two patients by nested-PCR-RFLP. At the time of progression, the T315I mutation represented 100% of the BCR-ABL transcripts. During follow-up, we showed that (i) despite a molecular response to IM, a high proportion of T315I transcripts were present (>85%) and predictive of relapse, (ii) interruption of IM and switching to other therapies resulted in a significant reduction in mutant transcript level while total BCR-ABL+ transcripts remained stable.

langue originaleAnglais
Pages (de - à)1073-1077
Nombre de pages5
journalLeukemia Research
Volume29
Numéro de publication9
Les DOIs
étatPublié - 1 sept. 2005
Modification externeOui

Contient cette citation